Peer-reviewed veterinary case report
Treatment of canine transmissible venereal tumour with interferon
By Kanca, Halit et al.·Published in Veterinary medicine and science·2018·Department of Obstetrics and Gynaecology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Intratumoral recombinant human interferon alpha-2a and vincristine combination therapy in canine transmissible venereal tumour.
- Species:
- dog
Plain-English summary
A group of 21 female dogs with a contagious tumor called canine transmissible venereal tumor (CTVT) were treated with different therapies to see which worked best. Some dogs received vincristine, a common chemotherapy drug, while others were given a combination of vincristine and a drug called recombinant human interferon alpha-2a (rhIFNα-2a). The combination treatment led to a quicker complete regression of the tumor compared to vincristine alone. Overall, while rhIFNα-2a alone didn't help, using it with vincristine made the treatment more effective and shorter in duration.
People also search for: dog tumor treatment · CTVT in dogs · vincristine for dog cancer · canine transmissible venereal tumor therapy
Abstract
Canine transmissible venereal tumour (CTVT) is a naturally occurring contagious neoplasm of dogs located mainly on the external genitalia of both sexes. The course of vincristine chemotherapy, the most effective and practical therapy, is affected by the immune status of the host. The aim was to investigate recombinant human interferon alpha-2a (rhIFNα-2a) and vincristine for treatment of CTVT. A total of 21 female dogs were included. In group I (n = 9), vincristine (0.025 mg/kg, IV) was administered weekly. In group II (n = 6), dogs were injected intratumorally weekly with 1.5 million IU rhIFNα-2a. In group III (n = 6), rhIFNα-2a and vincristine were combined. No tumour regression was observed after three injections of rhIFNα-2a in group II and weekly vincristine was administered. The number of tumour infiltrating lymphocytes (TILs), mitotic figures and apoptotic cells were counted in subsequent incisional tumour biopsies. The Kaplan-Meier Method was used to analyse survival using complete tumour regression as the outcome and Breslow Test was used for comparison of survival curves. Differences in TILs, cell proliferation and apoptosis between groups were assessed by analysis of covariance. Complete regression was observed in all animals included. Mean duration of vincristine treatment for complete regression was shorter in group II (3.50 weeks, 95% CI, 3.06-3.94, P < 0.05) and group III (3.17 weeks, 95% CI, 2.84-3.49, P < 0.01) compared to group I (5.11 weeks, 95% CI, 4.42-5.80). Vincristine and rhIFNα-2a combination increased TILs in CTVT biopsies compared to vincristine treatment (P = 0.017) and vincristine treatment after rhIFNα-2a (P = 0.049). Vincristine treatment after rhIFNα-2a (Group II; P < 0.001) and rhIFNα-2a and vincristine combination (Group III; P < 0.001) decreased apoptosis. The results indicate that intratumoral rhIFNα-2a treatment alone is not effective in CTVT. However, combination of rhIFNα-2a and vincristine shortens the duration of treatment compared to vincristine therapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30117719/